289 related articles for article (PubMed ID: 24189358)
1. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy.
Igarashi T; Shimizu A; Igarashi T; Hanaoka K; Yoshizaki K; Shigemori T; Shimizu S; Komeichi H; Itoh Y
J Nippon Med Sch; 2013; 80(5):387-95. PubMed ID: 24189358
[TBL] [Abstract][Full Text] [Related]
2. Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy.
Mahajan V; D'Cruz S; Nada R; Sachdev A
J Trop Pediatr; 2018 Jun; 64(3):249-252. PubMed ID: 28977667
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy.
Xiong QF; Zhong YD; Hu ZL; Yang YF
Acta Clin Belg; 2015 Jun; 70(3):223-5. PubMed ID: 25510219
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy.
Wang L; Xie B; Zheng Q; Xu L; Ye Z
Rev Esp Enferm Dig; 2020 Nov; 112(11):843-849. PubMed ID: 33054304
[TBL] [Abstract][Full Text] [Related]
5. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
6. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus-related membranous nephropathy treated with entecavir.
Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
[No Abstract] [Full Text] [Related]
8. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
9. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy.
Yang YF; Xiong QF; Zhao W; Zhong YD
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):e89-92. PubMed ID: 22572521
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
12. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.
Sun IO; Hong YA; Park HS; Choi SR; Chung BH; Park CW; Yang CW; Kim YS; Choi BS
Korean J Intern Med; 2012 Dec; 27(4):411-6. PubMed ID: 23269882
[TBL] [Abstract][Full Text] [Related]
13. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
Huang YW; Takahashi S; Tsuge M; Chen CL; Wang TC; Abe H; Hu JT; Chen DS; Yang SS; Chayama K; Kao JH
Antivir Ther; 2015; 20(4):369-75. PubMed ID: 24739420
[TBL] [Abstract][Full Text] [Related]
14. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
16. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
Shi M; Sun WL; Hua YY; Han B; Shi L
PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
[TBL] [Abstract][Full Text] [Related]
17. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
18. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
19. Early hepatitis B viral DNA clearance predicts treatment response at week 96.
Fu XY; Tan DM; Liu CM; Gu B; Hu LH; Peng ZT; Chen B; Xie YL; Gong HY; Hu XX; Yao LH; Xu XP; Fu ZY; He LQ; Li SH; Long YZ; Li DH; Gu JL; Peng SF
World J Gastroenterol; 2017 Apr; 23(16):2978-2986. PubMed ID: 28522916
[TBL] [Abstract][Full Text] [Related]
20. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
